BioArctic: Lecanemab phase 3 Clarity AD study in early Alzhe

STOCKHOLM, Sept. 28, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced positive topline results for the large global Phase 3 confirmatory Clarity

Related Keywords

China , Sweden , Japan , Stockholm , Uppsala , Uppsala Lan , Swedish , Oskar Bosson , Gunilla Osswald , Uppsala University , Vp Communications , National Institutes Of Health , National Institute On , Washington University School Of Medicine , Alzheimer Disease Cooperative Study , Alzheimer Network Trials Unit , Alzheimer Clinical Trial Consortium , Nasdaq Stockholm , Clinical Dementia Rating Sum , Clinical Trials , Confirm Safety , Participants With Early Alzheimer , From Baseline , Positron Emission Tomography , Disease Assessment Scale , Disease Composite Score , Disease Cooperative Study Activities , Daily Living Scale , Mild Cognitive Impairment , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited Alzheimer , Washington University School , Amyloid Related Imaging Abnormalities , Commercialization Agreement , Nasdaq Stockholm Mid Cap , Bioarctic , Lecanemab , Hase , Clarity , Study , Early , Lzheimer , Disease , Meets , Primary , Secondary , Endpoints , Thigh , Tatistical , Significance ,